Equity research · engineering · pharma/chemical equipment & AI datacentre diversification

Standard Engineering Technology

Strong core pharma/chemical-engineering growth continued, but a new, largely unproven AI-datacentre venture is now central to the investment case and a rich ~109x P/E.

Company: Standard Engineering Technology LtdReport Date: 13 September 2026Current Price: ₹468Symbol: NSE: SETL

Summary

Core view: Standard Engineering Technology grew Q1 FY27 revenue 41.5% and PAT 26.6% year-on-year, driven mainly by its core pharma/chemical-engineering equipment business, while a new AI-datacentre venture (GScale Energy) and an investment in Japan's GL Hakko are still early-stage. At about 109x trailing P/E, the market is already pricing in substantial success from these newer, unproven ventures, which is the central risk to monitor.

Standard Engineering Technology designs and manufactures process equipment for pharma and chemical customers, and is diversifying into AI-datacentre infrastructure (GScale Energy) and a Japan-based investment (GL Hakko Co.).

Q1 FY27 Snapshot

Revenue₹252.2 Cr+41.5% YoY
PAT₹26.7 Cr+26.6% YoY
EBITDA margin17.5%Q1 FY27
PAT margin10.6%Q1 FY27
MetricValue
Trailing P/E~109x
ROCE14.7%
ROE10.7%
FY27 core revenue guidance~₹1,200 Cr (upgraded)
FY27 consolidated target (incl. GScale)~₹1,450 Cr

Business Quality And Mix

Strengths

  • Strong core pharma/chemical-engineering revenue growth (+41.5% YoY).
  • Upgraded FY27 core revenue guidance to about ₹1,200 crore.
  • Diversification into AI-datacentre infrastructure (GScale Energy) offers new growth optionality.
  • Strong order book of about ₹1,400 crore in the core business.

Constraints

  • Trailing P/E of ~109x is very rich, pricing in substantial success from unproven new ventures.
  • GScale Energy (AI datacentre) and the Japan GL Hakko investment are both early-stage and unproven.
  • ROCE (14.7%) and ROE (10.7%) do not yet justify the current rich multiple on the core business alone.
  • No dividend declared, with cash being reinvested into diversification.

Growth Drivers And Capacity Economics

GScale Energy FY27 target~₹250 CrAI datacentre segment
Core order book~₹1,400 CrPharma/chemical engineering
FY27 consolidated target~₹1,450 CrCore + GScale Energy

Growth is being driven by strong core pharma/chemical-engineering equipment demand, alongside a new dual-growth strategy that adds AI-datacentre infrastructure (GScale Energy, targeted at ~₹250 crore FY27 revenue) and an investment in Japan's GL Hakko Co.

Management Guardrails And Credibility

ObjectiveTargetAssessment
Core revenue~₹1,200 Cr for FY27 (upgraded, 40-50% YoY)Supported by the current ~₹1,400 crore order book; a specific, credible management target for the established business.
GScale Energy (AI datacentre)~₹250 Cr FY27 revenue targetA new, largely unproven segment; execution risk here is materially higher than in the core engineering business.
Consolidated FY27 target~₹1,450 CrCombines the core business and GScale Energy; achieving this depends heavily on the newer segment's execution.

Financial Quality

ROCE14.7%Q1 FY27
ROE10.7%Q1 FY27
Trailing P/E~109xVery rich
Promoter holding60.5%High
Quality testReadingInterpretation
Earnings qualityPAT +26.6% YoY on strong core-business growthThe core pharma/chemical-engineering growth is genuine; the newer GScale Energy/GL Hakko ventures are not yet reflected meaningfully in reported earnings.
Returns vs valuationROCE 14.7%, ROE 10.7%, but ~109x P/ECurrent returns do not justify the multiple on the core business alone; the valuation is effectively an option on the new AI-datacentre venture succeeding.
Diversification riskGScale Energy and GL Hakko are early-stageA dual-growth strategy adds optionality but also meaningfully raises execution and capital-allocation risk versus a pure-play engineering business.

Valuation

Key Risks

  • GScale Energy (AI datacentre) execution failing to meet its ~₹250 crore FY27 target.
  • GL Hakko (Japan) investment not delivering expected value.
  • Very rich ~109x trailing valuation vulnerable to any disappointment in the new ventures.
  • Core pharma/chemical-engineering order-book conversion risk.
  • Capital allocation risk in funding two dissimilar growth vectors simultaneously.

Projection: Next 2-4 Quarters

Investor Watchlist

  • GScale Energy revenue contribution versus its ~₹250 crore FY27 target.
  • Core engineering order-book conversion.
  • ROCE/ROE trend relative to the ~109x trailing multiple.
  • GL Hakko investment progress and disclosure.
  • Capital allocation between the core business and new ventures.

Sources Used